ArticleInsights into imaging2026
Hyperechoic mesenteric fat on preoperative intestinal ultrasound predicts early postoperative recurrence in Crohn's disease.
Article in Insights into imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveTo investigate the value of hyperechoic mesenteric fat (HMF) detected by preoperative intestinal ultrasound (IUS) in predicting early postoperative recurrence (EPR) in patients with Crohn's disease (CD). MATERIALS AND
methodsThis retrospective study included 124 CD patients who underwent I-stage intestinal resection. Based on 1-year postoperative recurrence, patients were stratified into EPR (n = 59) and non-EPR (n = 65) groups. Clinical parameters (such as smoking history, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), immunosuppressive therapy) and IUS parameters (such as bowel wall thickness (BWT), HMF, abscess/fistula) were compared. Univariate and multivariate logistic regression identified EPR predictors.
resultsEPR occurred in 59 patients (47.6%) during the 1-year follow-up. Significant differences (p < 0.05) were observed between EPR and non-EPR groups for clinical factors (smoking history, elevated preoperative CRP/ESR, postoperative immunosuppression) and IUS parameters (HMF, BWT, and abscess/fistula). HMF demonstrated superior discriminative capacity for EPR prediction (area under the curve (AUC) = 0.808, 95% confidence interval (CI): 0.728-0.873) vs BWT (AUC = 0.618, p < 0.05) and abscess/fistula (AUC = 0.599, p < 0.05). Univariate analysis identified CRP, ESR, colonic disease, immunosuppression, HMF, abscess/fistula, and BWT as candidate predictors (p < 0.05), with multivariate analysis confirming HMF as an independent predictor (adjusted odds ratio (OR) = 18.810, 95% CI: 6.459-54.775; p < 0.001).
conclusionsPreoperative IUS-detected HMF may serve as a valuable predictor for assessing EPR risk in patients with CD. CRITICAL RELEVANCE STATEMENT: Preoperative IUS identification of HMF provides a practical, non-invasive biomarker that enables radiologists to critically improve risk stratification for EPR in CD. KEY POINTS: EPR poses a significant clinical challenge in the management of CD. HMF detected on preoperative IUS is a strong, independent predictor for EPR, with superior predictive performance compared to other established IUS parameters. Assessing HMF provides a valuable, non-invasive imaging biomarker for preoperative risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.